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Abstract: The prevalence of fungal infections has increased in immunocompromised patients, lead-
ing to millions of deaths annually. Arachidonic acid (AA) metabolites, such as eicosanoids, play
important roles in regulating innate and adaptative immune function, particularly since they can
function as virulence factors enhancing fungal colonization and are produced by mammalian and
lower eukaryotes, such as yeasts and other fungi (Candida albicans, Histoplasma capsulatum and Crypto-
coccus neoformans). C. albicans produces prostaglandins (PG), Leukotrienes (LT) and Resolvins (Rvs),
whereas the first two have been well documented in Cryptococcus sp. and H. capsulatum. In this
review, we cover the eicosanoids produced by the host and fungi during fungal infections. These
fungal-derived PGs have immunomodulatory functions analogous to their mammalian counterparts.
Prostaglandin E2 (PGE2) protects C. albicans and C. parapsilosis cells from the phagocytic and killing
activity of macrophages. H. capsulatum PGs augment the fungal burden and host mortality rates
in histoplasmosis. However, PGD2 potentiates the effects and production of LTB4, which is a very
potent neutrophil chemoattractant that enhances host responses. Altogether, these data suggest that
eicosanoids, mainly PGE2, may serve as a new potential target to combat diverse fungal infections.
Keywords: eicosanoids; immune response; fungi; fungal eicosanoids; pathogenesis
1. Introduction
Fungal infections are a major global threat, particularly due to their increasing preva-
lence in immunocompromised patients [1], the limited number of therapeutic options, their
chronicity, and frequently time-consuming diagnosis [2,3]. Classical virulence factors of
pathogenic fungi include the presence of urease, proteases, heat shock proteins, melanins
and a polysaccharidic capsule and other structures such as α-glucans and mannans, among
many others, which contribute to the spread of the pathogens and modulation of host
immune responses [4]. During fungal infections the role of inflammatory mediators such
as cytokines, growth factors and chemokines has been widely studied, and these prod-
ucts have been considered the main soluble protein mediators of host defense against
pathogens. However, the role of lipid mediators during fungal infections has not been fully
explored and a variety of unique lipids can also play important roles in regulating innate
and adaptive immune functions [5–7].
Biologically active lipid mediators derive from omega-3 (n-3) and omega-6 (n-6)
polyunsaturated fatty acids (PUFA) [8] and include the 20-carbon arachidonic acid (AA;
(20:4, n-6)) and eicosapentaenoic acid (EPA; (20:5, n-3))-derived eicosanoids and docosahex-
aenoic acid (DHA; 22:6(n-3))-derived docosanoids. These PUFAs, usually obtained from
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dietary sources or released from membrane phospholipids upon the hydrolysis of esterified
fatty acids (FAs) by phospholipase A2 (PLA2), can be oxidized by three distinct main
pathways involving cyclooxygenase (COX), lipoxygenase (LOX), and heme-containing
cytochrome P450 (CYTP450) oxidase or epoxygenase enzymes (Figure 1) [8]. Classic n-6
PUFA AA-derived eicosanoids participate actively during immune responses [4,9], and
can be classified into the prostanoids such as prostaglandins (PGs), prostacyclin (PGI2)
and thromboxanes (TXs), in addition to leukotrienes (LTs) and lipoxins [10]. In contrast
with lipoxins, which are formed from AA, the pro-resolving mediators (SPMs) such as
protectins, resolvins (RVs) and maresins [11] have n-3 PUFAs as their precursors, i.e., EPA
and DHA [12].
An important feature about AA-derived eicosanoids is their short response time, as
their formation does not require protein synthesis, due to the fact that the AA precursor is
present in mammalian cell membranes and the converting enzymes are usually constitu-
tively expressed. However, these compounds can also be produced by lower eukaryotes,
including yeasts and other fungi, having an active role during infection and representing a
potential class of virulence factors [4,13].
Prostaglandins (PGs) are five-carbon ring eicosanoids that are produced through the
conversion of AA to prostaglandin H2 (PGH2) by the cyclooxygenase-1 and -2 enzymes
(prostaglandin endoperoxide H synthases COX-1 and COX-2, respectively) [5]. Depending
on the following enzymatic step, PGH2 can be modified to produce different PGs (PGF2α,
PGD2, and PGE2), prostacyclin (PGI2) or thromboxane A2 (TXA2) [14]. They regulate
numerous processes throughout the body, such as kidney function, platelet aggregation,
neurotransmitter release, and modulation of inflammatory responses, where they partici-
pate, among other tasks, in thermoregulation (inducing fever) and pain [5]. PGs bind to
distinct types of GPCRs (G-protein coupled receptors), consisting of DP1 (Prostaglandin D2
receptor 1) and or CRTH2 (chemoattractant receptor-homologous molecule expressed on
Th2 cells; also known as DP2, PG DP2 receptor) that recognize PGD2, rhodopsin-type recep-
tors (EP1, EP2, EP3, EP4) that recognize PGE2, FP (prostaglandin F receptor) that recognizes
PGF2α, IP (prostacyclin receptor) that recognizes PGI2, and TP (thromboxane receptor) that
recognizes TXA2 [15–18]. These GPCRs generate several second messengers and trigger
distinct signal transduction pathways [19]. EP1 induces intracellular Ca2+ mobilization via
the Gq protein, whereas EP2 and EP4 increase cyclic adenosine monophosphate (cAMP)
production via Gs and EP3 inhibits adenyl cyclase (thus decreasing cAMP) via Gi and elicits
Ca2+ mobilization and phosphoinositide 3-kinase (PI3K) activation [15,20–23]. For these
reasons, they modulate the activation of protein kinase A (PKA), transcription factors such
as CREB [24], and extracellular signal-regulate kinases (ERKs) as well as the expression
of cytokines during the immune response [13,25,26]. PGE2 is the most studied PG, which
is produced by several cells such as macrophages and fibroblasts, and has diverse effects
on the regulation and activity of distinct cells [5]. For example, PGE2 can modulate the
activity of professional antigen presenting cells (APCs) such as dendritic cells (DCs) and
macrophages and the production of cytokines [5].
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Figure 1. Schematics of the eicosanoids synthesis pathway for the production of prostanoids (Prostaglandins—PGs, Prostacyclin and Thromboxanes—TXs), Leukotrienes (LTs) and
resolving mediators including D- and E-series resolvins (Rvs), protectins and maresins. The boxes depicted with bold borders illustrate the eicosanoids produced by fungi.
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Together with PGs in the prostanoid groups, thromboxanes (TXs) are produced as a
six-member ether-containing ring upon the catalysis of the thromboxane synthase (TXS),
producing the intermediate TXA2 or the final synthesis product TXB2 [10]. The thrombox-
ane receptor (T prostanoid receptor, TP) is a GPCR, with either a Gq or G12/13 coupled sub-
unit [10,27]. TXs are produced by several types of cells such as monocytes, macrophages,
epithelial, and endothelial cells as well as platelets (thrombocytes), promoting the ac-
tivation/aggregation and degranulation of platelets leading to the formation of blood
clots [10,28,29]. TXA2 is the most potent known vasoconstrictor, and its proinflammatory
action occurs by enhancing the activation of monocytes, cytokine production, expression
of leukocyte adhesion molecule, and vascular permeability [29]. TXA2 also promotes
T-cell activation and proliferation, and facilitates the development of effector cytolytic
T-cells [7]. For instance, TXA2 participates in the damage caused by ischemic injury and
inflammation in acute stages of Trypanosoma cruzi infections [29], exacerbates acute lung
injury by promoting edema formation [27] and its excessive production causes significant
hyper-permeability, resulting in severe edema by disrupting the endothelial barrier via
Ca2+/Rho kinase signaling [30]. In addition to these immunomodulatory functions, TXs
receptors (TPs) are expressed in high levels in the thymus where they participate in the
negative selection of maturing T lymphocytes [7,30].
Leukotrienes (LTs) are synthetized from AA by the enzyme 5-lipoxygenase (5-LO)
and 5-lipoxygenase activating protein (FLAP) into 5-hydroperoxyeicosatetraenoic acid
(5- HpETE), which is further metabolized into leukotriene A4 (LTA4), the precursor of
all forms of LTs [31]. LTA4 is converted by LTA4 hydrolase (LTA4H) into leukotriene
B4 (LTB4), or it can be conjugated with reduced glutathione by leukotriene C4 (LTC4)
synthase to yield the cysteinyl leukotriene (CysLT) LTC4 and its derivatives [31]. LTB4
and LTC4 are exported via the specific ATP-binding cassette (ABC) transporters-1 and -4,
whereas further released LTC4 is converted to leukotriene D4 (LTD4), which can undergo
further conversion into leukotriene E4 (LTE4) [31,32]. LT receptors are also GPCRs located
on the outer plasma membrane of resident and inflammatory cells, among other cell
types. They induce the increase in intracellular Ca2+ and the reduction in intracellular
cAMP levels [31,33,34]. LTB4 binds to BLT1 and BLT2 receptors, whereas the most known
receptor of cysteinyl LTs is the type 1 CysLT receptor (CysLTR1), with high affinity for
LTD4 and it is the target for antagonists clinically used for the management of asthma,
such as Montelukast, Zafirlukast and Pranlukast [31,32,34,35]. LTs play an important
role in amplifying the inflammatory responses to infection [31]. LTB4 participates in the
activation and recruitment of neutrophils, macrophages, monocytes, mast cells, and T
lymphocytes, while increasing phagocytosis, microbicidal activity, and generating and
modulating chemokines and cytokines [31]. It is one of the main modulators of the
activation and maintenance of the innate and adaptive immune response [35,36]. Fungal
zymosan and peptidoglycan from Aspergillus fumigatus induce the production of LTs
in the airways that contributes to the initiation of asthma and causes and exacerbates
potent bronchoconstrictive effects, such as edema through vasodilation, increased vascular
permeability, and enhanced recruitment of effector cells [37]. In contrast, gliotoxin from A.
fumigatus suppresses the biosynthesis of LTB4 by direct interference with LTA4H activity
resulting in impaired neutrophil functions [38–40].
Non-classical eicosanoids compose the group of specialized pro-resolving mediators
(SPM) also called resolvins (Rvs) [8]. SPMs derived from EPA are designated E-series
Rvs (Resolvin E1 or RvE1, RvE2 and RvE3), whereas those from DHA are referred to as
D-series RVs (RvD1-6) [12,41] (Figure 1). Four further metabolites of DHA have a hydroxyl
group at the 13-position and have been designated as 13-series resolvins (RvT). DHA is
converted to three Rvs of which RvD1(n-3DPA) is the most abundant [8]. RVs are involved
in the resolution stage of inflammation, ending the chronicity of the inflammatory process
and, hence, reducing or preventing tissue damage [11,12]. RvE1 is an eicosanoid that
protects human tissues from leukocyte regulated inflammatory processes [42–44]. RvE1
dramatically reduces dermal inflammation, peritonitis and interleukin (IL) production
J. Fungi 2021, 7, 254 5 of 16
and inflammatory pain [45]. RvE2 can effectively reduce joint pain in arthritis [11]. RvD2
ameliorates bacterial sepsis, with RvD3 acting in later stages of resolution and RvD4
helping the clearance of apoptotic cells by skin fibroblasts [8]. In general, RvDs also block
tumor necrosis factor (TNF)-α-induced IL-1β transcripts and are potent regulators of PMN
infiltration in brain, skin, and peritonitis in vivo [11,12].
2. Molecular Basis of Eicosanoid Production in Fungi
The molecular background of eicosanoid biosynthesis was first revealed in mam-
mals, with the description of three main enzymes pathways (COX, LO, and CYTP450) [46].
Eicosanoid production in yeasts was first uncovered in the early 1990′s in the non-pathogenic
fungus Dipodascopsis uninucleata. Van Dyk and colleagues isolated a 20-carbon chained AA
metabolite identified as 3-hydroxy-5,8,11,14- eicosatetraenoic acid (3-HETE) [47]. Later,
the same oxylipid was found in other yeasts of Dipodascaceae spp. and the filamentous
Mucor spp. and Rhizomucor spp. [48,49]. Noverr et al. [13] examined several pathogenic
fungi for the production of eicosanoids, and each analyzed species was able to produce
compounds that eluted together with mammalian PGs and LTs, in the absence and presence
of exogenous AA, by either, respectively de novo or a “trans-species” mechanism with
fungal phospholipases acting on host phospholipids (Figure 2) [6].




Figure 2. Eicosanoids production in Candida sp., Cryptococcus sp. and Histoplasma capsulatum. The 
figure illustrates genes involved in the synthesis of eicosanoids, with exception of H. capsulatum, 
with as yet undescribed genes involved. Lines and arrows indicate the eicosanoids produced by 
Candida sp. (solid lines), Cryptococcus sp. (dashed lines) and H. capsulatum (dotted lines). 
Besides C. albicans, several non-albicans Candida species such as C. dubliniensis, C. trop-
icalis, C. glabrata, and C. parapsilosis synthesize PGE2 [54–56], all of which are frequently 
associated with human fungal infections. HPLC-MS analysis of the fatty acid biosynthesis 
of C. parapsilosis by Grózer and colleagues revealed that this species, similar to C. albicans, 
is able to produce various PGs besides PGE2, and highlighted PGD2 as another major eico-
sanoid produced by C. parapsilosis [56]. A 2018 follow-up study with C. parapsilosis also 
identified an uncommon oxylipin, an autoxidative isomer of PGD2 (5-D2-IsoProstane) se-
creted upon incubation with exogenous AA (Figure 2) [57]. 
 However, our knowledge of its biosynthesis is scarce [58]. A recently published 
study by Chakraborty and colleagues aimed to identify the molecular basis of PG produc-
tion in C. parapsilosis and identified several genes involved in the process [57]. These in-
clude CPAR2_603600 (a homologue of the CaFET3), CPAR2_807710 (Acyl-CoA oxidase in 
S. cerevisiae, ScPOX1-3) and CPAR2_800020 (Acyl-CoA thiolase in S. cerevisiae, ScPOT1) 
(Figure 2). LC/MS data revealed that C. parapsilosis’ PGE2 biosynthesis is decreased by ap-
proximately 60–70% if any of these genes are disrupted. The double deletion of 
CPAR2_603600 and CPAR2_800020 leads to about 80% decrease in PGD2 production, sug-
gesting their significant role in its biosynthesis. Their removal also effected the secretion 
of 15-keto-PGE2, a metabolite generated by the degradation of PGE2. CPAR2_807710 was 
shown to be most involved in 15-keto-PGE2 production. In contrast to C. albicans, the hom-
ologue of CaOLE2 has no significant role in PGE2 biosynthesis in C. parapsilosis [56]. 
Notably, in addition to PGs, C. albicans also utilizes AA for the biosynthesis of LTs, 
such as LTB4 and CysLTs (Figure 2) [13]. During Candida spp. infection, the synthesis of 
some LTs is altered to reduce host immune responses as a strategy for the establishment 
and maintenance of the infection [35]. LTB4 and CysLT production are both mediated by 
lipoxygenases through the production of 5-HpETE from exogenous AA [13], whereas 
RvE1 synthesis in C. albicans is produced from EPA [42], and some biosynthetic precursors 
Figure 2. Eicosanoids production in Candida sp., Cryptococcus sp. and Hi to lasma cap ulatum. The figure illustrates genes
involved in the synthesis of eicosanoids, with exception of H. capsul tum, with as yet undescribed genes involved. Lines
and arrows indicate the ei osanoids produced by Candida sp. (solid lines), Cryp ococcus sp. (dashed lines) and H. capsulatum
(dotted li es).
However, whole genome sequencing analyses revealed that fungi have no homo-
logues for the abovementioned mammalian enzymes, suggesting that fungi have evolved
alternative routes for the synthesis of eicosanoids [46]. Yet, the use of COX inhibitors,
such as aspirin, indomethacin, and etodolac and the inhibition of the LO pathway with
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nordihydroguaiaretic acid inhibited eicosanoids production and clearly impacted growth
of Cryptococcus neoformans and Candida albicans, offering a link between fungal growth and
eicosanoid production [50–52].
2.1. Production of Eicosanoids by Candida albicans and Non-Albicans Species
Deva et al. revealed that the opportunistic human fungal pathogen C. albicans produces
3,18-dihydroxy-5,8,11,14- eicosatetraenoic acid (3,18-di-HETE) by utilizing exogenous
AA [53]. A subsequent study reported that, besides 3,18-di-HETE, C. albicans synthesizes
an uncharacterized prostaglandin (PGEx) [50]. This eicosanoid was later shown to be
indistinguishable from mammalian PGE2 [52]. Further investigations identified two non-
COX/LO/CYTP450-related enzymes, namely the fatty acid stearyl-coenzyme A desaturase
(Ole2) and the multicopper ferroxidase (Fet3), which are potentially involved in C. albicans
(Ca) PGE2 biosynthesis (Figure 2) [13,52]. Homozygous deletion of both the fatty acid
desaturase CaOLE2 and the multicopper oxidase CaFET3 resulted in a significant reduction
in PGE2 synthesis by approximately 50–70% and 40–50%, respectively. However, PGE2
levels were still measurable in the corresponding homozygous mutant suggesting the
presence of yet undiscovered PGs regulatory pathways in this species. C. albicans is also
able to produce other PGs, such as PGD2 and PGD2α [13,52].
Besides C. albicans, several non-albicans Candida species such as C. dubliniensis, C.
tropicalis, C. glabrata, and C. parapsilosis synthesize PGE2 [54–56], all of which are frequently
associated with human fungal infections. HPLC-MS analysis of the fatty acid biosynthesis
of C. parapsilosis by Grózer and colleagues revealed that this species, similar to C. albicans,
is able to produce various PGs besides PGE2, and highlighted PGD2 as another major
eicosanoid produced by C. parapsilosis [56]. A 2018 follow-up study with C. parapsilosis
also identified an uncommon oxylipin, an autoxidative isomer of PGD2 (5-D2-IsoProstane)
secreted upon incubation with exogenous AA (Figure 2) [57].
However, our knowledge of its biosynthesis is scarce [58]. A recently published study
by Chakraborty and colleagues aimed to identify the molecular basis of PG production
in C. parapsilosis and identified several genes involved in the process [57]. These include
CPAR2_603600 (a homologue of the CaFET3), CPAR2_807710 (Acyl-CoA oxidase in S. cere-
visiae, ScPOX1-3) and CPAR2_800020 (Acyl-CoA thiolase in S. cerevisiae, ScPOT1) (Figure 2).
LC/MS data revealed that C. parapsilosis’ PGE2 biosynthesis is decreased by approximately
60–70% if any of these genes are disrupted. The double deletion of CPAR2_603600 and
CPAR2_800020 leads to about 80% decrease in PGD2 production, suggesting their signifi-
cant role in its biosynthesis. Their removal also effected the secretion of 15-keto-PGE2, a
metabolite generated by the degradation of PGE2. CPAR2_807710 was shown to be most
involved in 15-keto-PGE2 production. In contrast to C. albicans, the homologue of CaOLE2
has no significant role in PGE2 biosynthesis in C. parapsilosis [56].
Notably, in addition to PGs, C. albicans also utilizes AA for the biosynthesis of LTs, such
as LTB4 and CysLTs (Figure 2) [13]. During Candida spp. infection, the synthesis of some LTs
is altered to reduce host immune responses as a strategy for the establishment and mainte-
nance of the infection [35]. LTB4 and CysLT production are both mediated by lipoxygenases
through the production of 5-HpETE from exogenous AA [13], whereas RvE1 synthesis in C.
albicans is produced from EPA [42], and some biosynthetic precursors (18-HEPE, 15-HEPE
and 5-HEPE), by neutrophil 5-lipoxygenase principally, cytochrome P450 monooxygenase
enzymes (CYP45), and other specific enzymes remain unknown [13,42,59]. The detailed
biosynthetic pathway of LTs and RvE1 in C. albicans also remains enigmatic. Other human
pathogenic non-albicans Candida species such as C. dubliniensis, C. tropicalis, and C. glabrata
may also be able to produce these eicosanoids; however, this remains unconfirmed.
2.2. Production of Eicosanoids by Cryptococcus sp.
C. neoformans produces biologically active eicosanoids from exogenous sources of
AA during infection, which are indistinguishable from host eicosanoids and modulate
host defenses [50,51]. The major AA metabolite produced is an authentic PGD2, but
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the fungus is also able to produce heptadecatrienoic acid, 5-HETE, PGF2, TXB2, and
PGE2 [50]. Two enzymes expressed by C. neoformans, phospholipase B1 (PLB1) and laccase
(CNLAC1 gene), are believed to be associated with cryptococcal eicosanoid synthesis
(Figure 2). Pharmacological enzymatic inhibition or deletion of phospholipase B1 (∆plb1)
reduces secreted levels of all eicosanoids produced by C. neoformans [60,61]. In turn,
deletion of laccase (∆lac1 mutants) or enzymatic inhibition by anti-lac1 antibody resulted
specifically in the loss of PGE2 [51]. The addition of PGE2 was sufficient to promote
growth of ∆plb1 and ∆lac1 in vitro and in vivo, independently of host PGE2 [60,61]. In fact,
laccase is an important virulence factor for C. neoformans with a broad spectrum oxidase
activity, converting polyphenolic compounds into the cell wall pigment melanin, and this
polymer protects C. neoformans against oxidants, microbiocidal proteins and antifungals
as well as to phagocytosis and killing by macrophages [62,63]. Additionally, recombinant
laccase readily converts PGG2 into PGE2 and 15-keto-PGE2, and it is suggested as a key
cryptococcal prostaglandin enzyme for this recently described unique production pathway
(Figure 2) [51].
2.3. Production of Eicosanoids by Histoplasma Capsulatum
Although Histoplasma capsulatum can produce eicosanoids [13,54], further studies are
necessary to dissect the pathways involved in their production and to determine whether
they play a role during infection (Figure 2).
3. The Role of Eicosanoids during Fungal Infections
The production of eicosanoids by pathogenic fungi, such as C. albicans, C. dubliniensis,
C. glabrata, C. tropicalis, C. neoformans, H. capsulatum and A. fumigatus is linked to the
pathogenesis of each fungal infection [4,9,51,60,64–66]. Some fungal-derived eicosanoids
can enhance both fungal colonization and induce immunomodulatory effects. Overall,
fungal LTs act by enhancing the acute inflammation, whereas PGs have negative effects on
innate and cellular Th1 responses against mycosis, resulting in immunological tolerance
and contributing to the chronicity of fungal infections [13]. Herein, we discuss the roles of
eicosanoids in three major fungal infections.
3.1. Eicosanoids in Candidiasis
Eicosanoids play an important role in both sides of the host–Candida interaction.
Depending on the organ or tissue environment, host-derived PGE2 either decreases [64,67]
or improves [68,69] the protective Th1 and Th17 responses that particularly may help the
host restrain C. albicans at barrier surfaces and in the bloodstream.
C. albicans induces host cells to release AA from membrane phospholipids and
infection-derived stimuli can also induce COX-2 expression and trigger the synthesis
of PGs in various cells types [66,70]. C. albicans stimulates AA metabolism and the genera-
tion of PGE2 by synovial fibroblast, alveolar and peritoneal macrophages, and epithelial
cells via stimulation of TLR2 and TLR4 [14]. Candida mannans and β-1,3-glucan induce
PGE2 via stimulation of mannose receptor and dectin-1 in peripheral blood mononuclear
cells, respectively [71]. PGE2 signaling stimulates Th2 and Th17 responses to yeast and
limits the ability of macrophages to clear Candida sp. [71].
Although the exact role of Candida-derived eicosanoids during host–pathogen inter-
actions is largely undiscovered, a limited number of studies are available that provide
insights into how these lipid metabolites affect fungal virulence [57,67]. Many studies have
pointed out the major role of host derived AA and fungi derived PGE2 in the modulation of
yeast cell growth, morphogenesis, and biofilm formation in C. albicans [50,55]. In contrast,
some studies focusing on the negative impact of PGE2 on yeast biology have shown that
PGE2 inhibits germ tube formation by antagonizing yeast to hyphal transformation in C.
albicans, which may limit tissue invasion [72].
In a previous study, the PGE2 biosynthesis associated genes OLE2, FET3, and FET31
were knocked out in C. albicans strains and the mutant’s capacity for PGE2 secretion was
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decreased in vitro. The authors examined the killing of the mutants by macrophages
and immune-modulatory effects in vitro as well as their capacity for organ colonization
ability in various mouse models of invasive candidiasis. The ole2−/− showed similar fitness
and rates of hyphal formation than the wild-type (WT) counterpart. However, the gut
colonizing capacity of the ole2−/− strain decreased compared to the WT strain. Besides its
role in promoting colonization and survival in the mouse gut, C. albicans derived PGE2
also inhibited fungal cell internalization by phagocytes [65]. However, in CD11b+ DC
and macrophage depleted mice, the WT C. albicans strain was not able to overgrow the
ole2−/− strain [65], suggesting that the presence of PGE2 is beneficial for fungal growth,
overcoming phagocytosis, and enhancing survival within the host.
Regarding non-albicans Candida species, the presence of AA increases biofilm forma-
tion and PGE2 production by C. glabrata, C. parapsilosis, and C. tropicalis [58]. These findings
suggest that Candida spp. evolved the capacity to produce PGs, primarily PGE2, to enhance
their fitness and survival within certain niches of the host that could directly promote the
fungus’ pathogenesis upon a potential commensal-to-pathogenic shift event. The work of
Chakraborty and colleagues suggests that fungal-derived PGs in C. parapsilosis also nega-
tively regulate yeast cell phagocytosis and killing by macrophages, as PGs (PGE2, PGD2,
and 15-keto-PGE2)-deficient C. parapsilosis cells were more susceptible to phagocytosis and
killing by human peripheral blood monocyte-derived macrophages (PBMC-DM) compared
to the WT strain [57]. As the virulence of PG deficient C. parapsilosis mutant strains also
decreased in vivo compared to the WT strain, fungal PGs could also actively contribute to
the virulence of this species.
These observations, together with other previous reports, suggest that fungi-derived
prostaglandins have immunomodulatory functions analogous to their mammalian coun-
terparts [54,73]. To further support this suggestion, another study reported that C. albi-
cans-produced PGE2 up-regulates anti-inflammatory responses through enhancing IL-10
released by murine splenocytes. Moreover, the levels of mouse keratinocyte-derived
chemokine (KC, analog to human IL-8) and other pro-inflammatory cytokines, such as
TNFα, decreased after 24 h of fungal PGE2 treatment [67,71]. Fungal-derived PGE2 de-
creases the killing of C. albicans by intestinal macrophages, supporting the idea that fungal
prostaglandins could also inhibit the killing activity of host cells.
A similar conclusion can be drawn for C. parapsilosis, where the absence of PGE2
-related genes increased the expression of pro-inflammatory cytokines such as pro-IL-
1β, IL-6 and TNFα [57]. Thus, C. parapsilosis PGE2 could also negatively regulate host
inflammatory responses. In C. parapsilosis, PGs production actively contributes to host
cell damage, as revealed by the decreased [57] death of PBMC-DMs following infection
with PG-deficient strains compared to the WT strain. C. parapsilosis PGs secretion is also
suggested to contribute to organ colonization when studied in a mouse model of systemic
candidiasis. However, the studied PG-related genes contributed unequally to the fungal
load of each examined organ, which may suggest that the observed effect is not solely due
to the presence of fungal PGE2, PGD2 and 15-keto-PGE2 [57].
LTs were also described as biologically active immunomodulatory eicosanoids [74,75].
Host-derived LTs increase capillary permeability, and activate and recruit eosinophils and
neutrophils [75]. The present literature lacks information about the immunomodulatory
function of fungal-derived LTs. However, a recent study showed that the amount of LTF4
increased in patients with candidemia, suggesting that LTF4 may also contribute to host
responses to Candida spp. [35].
A previous study in 2007 showed that C. albicans-derived RvE1 is chemically iden-
tical to the human RvE1 [42]. When administered at low concentrations, fungal RvE1
reduced the IL-8-mediated chemotaxis of human neutrophils and also the recruitment of
DCs [42,59]. In contrast, higher doses of fungal RvE1 enhanced phagocytic activity and
fungicidal reactive oxygen species (ROS) production by human neutrophils against C.
albicans. Interestingly, inoculation of RvE1 into mice with fungemia due to C. albicans, led to
a more rapid clearance of the pathogen from the bloodstream [42]. These facts suggest that
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low concentrations of fungal RvE1 protects C. albicans due to the inhibition of neutrophil
recruitment, although higher fungal burden (together with increased fungal RvE1 levels)
could act as an alarming signal for neutrophils, which would then be able to control and
restrict fungal invasion.
3.2. Eicosanoids in Cryptococcosis
C. neoformans secretes phospholipase B (PLB), which is a virulence factor. This sin-
gle cryptococcal protein has three separate enzymatic activities: phospholipase B (PLB),
which removes both acyl chains simultaneously from phospholipids; lysophospholipase
(LPL), which removes the single acyl chain from lysophospholipids; and lysophospholipase
transacylase (LPTA), which adds an acyl chain to lysophospholipids to form phospho-
lipids [61]. Despite the lack of understanding on the structure and mechanism of action
of PLB, this enzyme is involved in the survival of Cryptococci within macrophages, the
destruction of lung tissue and the production of eicosanoids, which modulate phagocytic
activity [61]. As mentioned, C. neoformans produces eicosanoids from exogenous AA and
utilizes them to modulate the immune response favoring its own survival. For instance,
LTB4 significantly reduced neutrophil recruitment in the lung vasculature of mice infected
intravenously with C. neoformans, demonstrating a critical role of LTB4 in intravascular
neutrophil swarming during infection [76]. The presence of CysLTs and LTB4 produced by
C. neoformans strains B-3501A and H99 through the activity cryptococcal phospholipase
cPLA2α and 5-LO, can contribute to fungal penetration of the blood–brain barrier in vitro
and in vivo, specifically facilitating central nervous system (CNS) infection [77].
C. neoformans is also able to modulate the host inflammatory state during infection
by directly manipulating host eicosanoids signaling and PGE2 is considered a mediator of
cryptococcal virulence [60,78]. During macrophages infection, C. neoformans produces the
dehydrogenated form of PGE2 (15-keto-PGE2) enhancing its virulence via the activation of
the host nuclear transcription factor, PPAR-γ [60]. In C. neoformans infections, the use of
antagonists of either EP2 or EP4 receptors improves the host defense by promoting TLR-4-
mediated cytokine production, and enhancing M1 macrophage polarization followed by
yeast killing [78].
3.3. Eicosanoids in Histoplasmosis
A 1992 study showed that peritoneal macrophages challenged with heat-killed H.
capsulatum produce prostanoids (PGE2 and PGI2) and LTs (LTB4 and LTC4), the former
being produced in a COX-dependent fashion [79]. This first observation was the stepping-
stone for the study of eicosanoids in histoplasmosis. Notably, different forms of LTs and
PGs are produced by the host during in vitro and in vivo challenges with H. capsulatum,
but, interestingly, they commonly have opposite roles [80,81].
Sub-lethal H. capsulatum infections in mice treated with a FLAP inhibitor or in 5-
LO deficient mice are fatal, suggesting that LTs are important for the host response in
histoplasmosis [81,82]. Even though LTB4 and LTC4 are produced in mice infected with H.
capsulatum [81], data show that administration of microspheres-associated LTB4 to 5-LO
deficient mice can restore the production of cytokines and control the fungal burden [83].
Although LTB4 is an important mediator for the host response against H. capsulatum,
the mechanism behind its effects is controversial. LTB4 is a very potent neutrophil chemoat-
tractant [84], but 5-LO deficient mice and mice treated with FLAP inhibitors have lower
levels of LTs and increased neutrophil recruitment when compared to their control counter-
parts. The increased neutrophil recruitment is followed by higher inflammatory response,
an elevation of splenic fungal burdens, and 100% of mortality 14 days post-infection, even
in scenarios of non-lethal H. capsulatum infections [81,82]. This suggests that features other
than neutrophil chemotaxis are behind LTs’ effects during histoplasmosis. The effector
mechanisms employed by macrophages are also responsive to LTs, as 5-LO deficient mice
have a remarkable impairment in their ability to phagocytose non-opsonized or even
IgG-opsonized H. capsulatum yeast cells, a deficiency that is bypassed by the exogenous
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addition of LTB4 or LTC4 [82]. Although LTs as well as PGs are usually produced at the
onset of the inflammatory process, further steps in the host defense are modulated by the
presence of these mediators [85]. Immunization of mice with cell-free antigens from H.
capsulatum fails to confer protection in 5-LO deficient mice, possibly due to an inability to
induce the recruitment of CD4+ and CD8+ cells to the lungs, and also a failure to increase
the production of IFN-γ [86]. The production of LTs has an impact on events of the innate,
but also of the adaptive, response during H. capsulatum infection, which modifies the
outcome of the host–pathogen interaction.
The role of PGs during H. capsulatum infection is not as well studied relative to the
leukotrienes. A fundamental piece of data is that the inhibition of COX-2 protects mice
against lethal infection with H. capsulatum, a phenotype marked by lower fungal burden
and a milder inflammatory process [80]. Curiously, when inhibiting the synthesis of
prostanoids, an increase in the synthesis of LTB4 is observed, which is also beneficial to the
host. The higher survival rates are associated with a decrease in neutrophil recruitment,
consistent with the effects of LTs [80]. PGE2 has been associated with the deleterious effects
on H. capsulatum infection [16], which correlates with the expression and activity of galectin-
1 (Gal-1) [87]. Gal-1 represses the expression of PGE2 synthase, thus reducing the levels of
PGE2 in H. capsulatum-infected mice. In contrast, H. capsulatum infection in Gal-1 KO mice
leads to an increase in PGE2 production followed by increased fungal burden and higher
mortality rates when compared to WT mice [87]. Even though PGE2 has such deleterious
effects to the infected host, PGD2 has opposite effects to PGE2. The pharmacological
inhibition of the endogenous production of PGD2 in H. capsulatum-infected macrophages
leads to a severe inhibition of the leukocyte’s fungicidal activity, an effect that is reversed
by the exogenous addition of PGD2. PGD2 also upregulates the expression of LTB4 receptor
(BLT1R), potentiating the effects of LTB4 [87]. The role and mechanism of eicosanoids
in the host response against H. capsulatum is still understudied, but data suggest that
LTB4 and PGE2 have opposite effects in histoplasmosis by modulating the recruitment
of neutrophils and the effector mechanisms of macrophages. In agreement, PGE2 also
inhibits the production of hydrogen peroxide and TNF-α by monocytes, limiting the killing
of Paracoccidioides brasiliensis [88]. Further studies are necessary to dissect whether other
eicosanoids have a role in the infection by H. capsulatum, including ones of fungal origin
and also the mechanisms involved in immune regulation.
4. Concluding Remarks
Human pathogenic fungal species such as Candida spp., C. neoformans and H. capsu-
latum produce eicosanoids. C. albicans utilizes exogenous AA in order to produce 3,18-di
HET, LTB4, Cys-LTs, RvE1 and prostaglandins such as PGE2, PGD2, PGF2α. Non-albicans
Candida species such as C. dubliniensis, C. tropicalis, C. glabrata, and C. parapsilosis also
synthesize PGE2 from AA. Additionally, C. parapsilosis produces other prostaglandins such
as PGD2 and 15-keto-PGE2. The exact molecular mechanisms behind the Candida-derived
eicosanoid production are only uncovered in the case of PGs in C. albicans and C. parap-
silosis. PGE2 synthesis in C. albicans is regulated by OLE2, while C. parapsilosis evolved
OLE2-independent PGs production pathways. This difference may explain the contrast in
in vivo results: C. albicans-derived PGE2 is not required for virulence while PGs produced
by C. parapsilosis influence the yeast’s capacity for host damage. Overall, the presence
of fungal PGE2 has proven to be beneficial for C. albicans through increasing the ability
of the pathogen to colonize the gut. Furthermore, fungal PGE2 protects C. albicans and
C. parapsilosis cells from the phagocytic and killing activity of macrophages. C. albicans-
derived RvE1 protects the fungus at low concentrations, whereas high concentrations
expose the fungus to the host. C. neoformans produces 15-Keto-PGE2 to enhance its growth
and ability to survive macrophage infection. In histoplasmosis, the inhibition of the PGs
production is beneficial to the host as it favors LTB4 production, which induces a decrease
in the fungal burden, mortality rates and neutrophil recruitment. PGE2 has deleterious
effects on histoplasmosis, as opposed to the positive effects of PGD2, which upregulates the
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expression of BLT1R in H. capsulatum infected macrophages and potentiates the effects of
LTB4. LTs are important for the host response, as, for example, LTB4 mediates the immune
response helping to control the fungal burden. However, the mechanism behind its effect
is controversial as LTB4 is a neutrophil chemoattractant and mice with lower levels of LTs
have increased inflammatory responses, fungal burdens and mortality rates. However,
further investigations are needed to understand the precise role of eicosanoids, mainly
PGE2, during host–pathogen interactions.
5. Future Trends
The production of eicosanoids seems to be a conserved feature among several eukary-
otic organisms, including filamentous and yeast fungi, protozoa and higher eukaryotes
such as mammals. Independently on the organism, their biosynthetic pathways may
vary considerably, as well as the full eicosanoid portfolio produced. Since pathogenic
fungi are able to secrete these molecules, the exact mechanism in how they alter the mi-
crobial physiology has not been fully explored, although current research and published
data have demonstrated their effects on the modulation of interactions with the host and
immune responses.
Then, as it is completely plausible that fungal eicosanoids might function as virulence
factors, further investigations might enable us to understand their precise role during
host–pathogen interactions, as well as exploring the unique steps of the fungal eicosanoids
biosynthesis, as a new potential target to combat C. albicans, C. parapsilosis, C. neoformans
and H. capsulatum and possibly other fungal infections.
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Abbreviations
15-keto-PGE2 Dehydrogenated form of Prostaglandin E2
3-HETE 3-hydroxy-5,8,11,14- eicosatetraenoic acid
3,18-di-HETE 3,18-dihydroxy-5,8,11,14- eicosatetraenoic acid
5- HpETE 5-hydroperoxyeicosatetraenoic acid
5-LO Enzyme 5-lipoxygenase
AA Arachidonic acid
AA (20:4, n-6) Arachidonic acid (20-carbon, 4 insaturations, omega 6 family)
ABC ATP-binding cassette transporter
APCs Antigen presenting cells
BLT1 Leukotriene B4 high-affinity receptor
BLT2 Leukotriene B4 Low-affinity receptor
CaFET3 Candida albicans multicopper ferroxidase
cAMP Cyclic adenosine monophosphate
CaOLE2 C. albicans fatty acid stearyl-coenzyme A desaturase
CNLAC1 Cryptococcus neoformans laccase gene
CNS Central nervous system
COX Cyclooxygenase
CRTH2 Chemoattractant receptor-homologous molecule expressed on Th2 cells;
also known as DP2, PG DP2 receptor
J. Fungi 2021, 7, 254 12 of 16
CysLT Cysteinyl leukotriene
CysLTR1 Type 1 cysteinyl leukotriene receptor
CYTP450 Cytochrome P450 oxidase
DCs Dendritic cells
DHA Docosahexaenoic acid
DP1 Prostaglandin D2 receptor 1
EP (1-4) Rhodopsin-type receptors
EPA Eicosapentaenoic acid
ERKs Extracellular signal-regulate kinases
FAs Fatty acids
FLA 5-lipoxygenase activating protein
FP Prostaglandin F receptor
Gal-1 Galectin-1






























PUFA Polyunsaturated fatty acids
Rvs Resolvins
RvD D-series Resolvins (RvD1-6)
RvE1 E-series Resolvins (RvE1-3)
RvT 13-series resolvins
SPM Specialized pro-resolving mediator
Th T-helper





∆lac1 Laccase gene Cryptococcus neoformans mutant
∆plb1 Phospholipase B1 Cryptococcus neoformans mutant
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